ScreenerHero

ATRA Atara Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · atarabio.com
9.370USD-3.90%Mkt Cap: 94.05M $P/E: —

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleuce…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap94.05M USD
Enterprise Value97.87M USD
Revenue (TTM)6.19M USD
Gross Profit99.56M USD
Net Income (TTM)32.69M USD
Revenue/Share0.44 USD
Last Price9.370 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)6.31
PEG—
EV/EBITDA-8.85
EV/Revenue15.80
P/S15.80
P/B-2.49
EPS (TTM)-1.35
EPS (Forward)1.54
52W Range
3.92036% of range19.14
52W High19.14 USD
52W Low3.920 USD
Profitability
Gross Margin82.44%
Oper. Margin-627.46%
EBITDA Margin-178.53%
Profit Margin27.07%
ROE-84.90%
ROA161.54%
Growth
Revenue Growth-96.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.94M USD
CapEx (TTM)—
FCF Margin-202.17%
FCF Yield-13.31%
Net Debt6.00K USD
Net Debt/EBITDA-0.00
Balance Sheet
Debt/Equity-0.27
Current Ratio1.98
Quick Ratio1.49
Book Value/Sh-3.92 USD
Cash/Share0.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 20, 2024
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.67 USD
Upside (mean)+45.9%
Target Range10.00 USD – 18.00 USD
10.00+45.9% to mean18.00
# Analysts3
Ownership
Shares Out.10.04M
Float4.62M
Insiders16.80%
Institutions57.67%
Short Interest
Short Ratio8.5d
Short % Float5.50%
Short % Out.4.03%
Shares Short404.27K
Short (prev mo.)477.27K
Technical
SMA 508.994 (+4.2%)
SMA 2008.246 (+13.6%)
Beta0.22
S&P 52W Chg16.45%
Avg Vol (30d)48.62K
Avg Vol (10d)44.49K
Technical Indicators
RSI (14)53.3
MACD0.0220
MACD Signal-0.0464
MACD Hist.+0.0684
BB Upper10.38 USD
BB Middle9.169 USD
BB Lower7.959 USD
BB Width26.40%
ATR (14)0.7155 USD
Vol Ratio (20d)0.21x